Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7053363 | 1.00 | CA1 (0.50) | CA1CA9CYP2D6SMN1; SMN2ALDH1A1 | |
| SCHEMBL7054979 | 1.00 | CA1 (0.50) | CA1CA9CYP2D6SMN1; SMN2ALDH1A1 | |
| SCHEMBL7056917 | 1.00 | CA1 (0.50) | CA1CA9CYP2D6SMN1; SMN2ALDH1A1 | |
| SCHEMBL31459238 | 1.00 | CA1 (0.50) | CA1CA9CYP2D6SMN1; SMN2ALDH1A1 | |
| SCHEMBL18864298 | 1.00 | CA1 (0.50) | CA1CA9CYP2D6SMN1; SMN2ALDH1A1 | |
| SCHEMBL7056509 | 1.00 | CA1 (0.50) | CA1CA9CYP2D6SMN1; SMN2ALDH1A1 | |
| SCHEMBL7057493 | 1.00 | CA1 (0.50) | CA1CA9CYP2D6SMN1; SMN2ALDH1A1 | |
| SCHEMBL7059510 | 1.00 | CA1 (0.50) | CA1CA9CYP2D6SMN1; SMN2ALDH1A1 | |
| SCHEMBL1046752 | 1.00 | CA1 (0.50) | CA1CA9CYP2D6SMN1; SMN2ALDH1A1 | |
| SCHEMBL7053748 | 1.00 | CA1 (0.50) | CA1CA9CYP2D6SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6639089-B2 | Therapy, side effect reduction | SODA AROMATIC CO., LTD. | 2003-10-28 | — | — | US | claimed |
| US-20030055105-A1 | Anticancer agents, perfumes or foods and drinks containing omega-hydroxyfatty acids | SODA AROMATIC CO., LTD. A JAPANESE CORPORATION (JP) | 2003-03-20 | — | — | US | claimed |
| EP-1249236-A1 | ANTICANCER AGENTS, PERFUMES OR FOODS AND DRINKS CONTAINING $g(v)-HYDROXYFATTY ACIDS | SODA AROMATIC COMPANY, LIMITED (JP) | 2002-10-16 | — | — | EP | claimed |
| US-6639089-B2 | Therapy, side effect reduction | SODA AROMATIC CO., LTD. | 2003-10-28 | — | — | US | disclosed |
| US-20030055105-A1 | Anticancer agents, perfumes or foods and drinks containing omega-hydroxyfatty acids | SODA AROMATIC CO., LTD. A JAPANESE CORPORATION (JP) | 2003-03-20 | — | — | US | disclosed |
| EP-1249236-A1 | ANTICANCER AGENTS, PERFUMES OR FOODS AND DRINKS CONTAINING $g(v)-HYDROXYFATTY ACIDS | SODA AROMATIC COMPANY, LIMITED (JP) | 2002-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055105-A1 | Anticancer agents, perfumes or foods and drinks containing omega-hydroxyfatty acids | ALOX5, ELOVL5, ELOVL3 | CA1 1636/4885CA9 1111/4885CYP2D6 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.